 IGM Biosciences NASDAQ:IGMS has been given a consensus rating of Buy by the twelve ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock ... 